Phase 4 N=18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Glucagon Use in Colonoscopies
Colon Cancer
Primary: Adenoma Detection Rate (ADR) During Colonoscopy Procedure — 43.75; 33.33 percentage of participants
Phase 4 N=11 PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers
Chronic Pain
Primary: Oxytocin Concentration — 1047 pg/ml
Phase 4 N=30 Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
Inflammation · Fatigue
Primary: Central Nervous System (CNS) Glutamate Measured by Magnetic Resonance Spectroscopy (MRS) — 1.26; 1.2; 1.26; 1.27 Glu/Cr
Phase 4 N=103 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
Rabies
Primary: Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group…
Phase 4 N=22 A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Residual Volume (RV) at 6 Hours Postdose — 0.004; -0.319 L — p=0.0987
Phase 4 N=982 Standardized Treatment of Pulmonary Exacerbations II
Pulmonary Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day — 13.30; 13.83 percentage change — p=0.0164
Phase 4 N=30 NIRS Ticagrelor Evaluation
Coronary Artery Disease
Primary: Change From Baseline Lipid Pool to Follow up as Assessed by NIRS/IVUS With Treatment of Ticagrelor
Phase 4 N=69 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
Neuromuscular Blockade · Anesthesia
Primary: Time in Minutes to Reach Train of Four (TOF) Ratio ≥ 0.9 After the Administration of Reversal Agent — 8; 3 minutes — p=<0.001
Phase 4 N=798 Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Heart Disease
Primary: Number of Patients With Atrial Arrhythmia — 121; 134 Participants — p=0.34
Phase 4 N=315 PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)
Atrial Fibrillation
Primary: Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications at Six Months After the Index Procedure — 99; 98 Participants
Phase 4 N=75 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Hyperlipidemia · Insulin Resistance · Type 2 Diabetes
Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01
Phase 4 N=12 Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
Anaphylaxis
Primary: Plasma Catecholamine Levels (Maximum Concentration, Cmax) — 218; 394; 290 pg/ml
Phase 4 N=10 Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin
Chronic Pain
Primary: Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection — 22; 21 Hz — p=0.83
Phase 4 N=120 Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres